Evidence map›Paper›PMID 17117175›Full record

SynthesisBritish journal of cancer2006

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis.

M Aapro, B Coiffier, J Dunst, A Osterborg, H U Burger

Registry-linked trialOpen access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00875004 (Research Factors Predictive of Treatment Failure With Erythropoietin Beta), which is not on this map. Cited by 8 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00875004 naterminatednot on this mapstarted 2007, after this paper: background citation

Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2007 to 2011Enrolled27ConditionsAnemia, Unspecified Adult Solid Tumor, Protocol SpecificArmsepoetin beta, systemic chemotherapy, quality-of-life assessment
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews · 2012
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumours.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011
    Article
  7. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

M AaproInstitut Multidisciplinaire d'Oncologie, Clinique de Genolier, 1, route du Muids, CH-1272 Genolier, Switzerland. maapro@genolier.net
B Coiffier
J Dunst
A Osterborg
H U Burger
Clinique de Genolier · CHHôpital Lyon Sud · FRKarolinska University Hospital · SEMartin Luther University Halle-Wittenberg · DERoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the early effect of epoetin beta on survival and tumour progression in anaemic patients with cancer, data were pooled from nine randomised clinical trials comparing epoetin beta with placebo or standard care. Studies were not primarily designed to assess these end points. Follow-up was for treatment duration plus 4 weeks following therapy completion. All adverse events (AEs) were retrospectively reviewed blinded, for progression. Thromboembolic events were also assessed. Data analysis involved standard statistical tests. Overall, 1413 patients were included (epoetin beta, n = 800; control, n = 613; 56% haematological, and 44% solid). Median initial epoetin beta dose was 30,000 IU/week. Overall survival during months 0-6 was similar with epoetin beta and control (0.31 vs 0.32 deaths/patient-year). No increased mortality risk was seen with epoetin beta (relative risk (RR) 0.97, 95% CI: 0.69, 1.36; P = 0.87). There was a significantly reduced risk of rapidly progressive disease for epoetin beta (RR 0.78, 95% CI: 0.62, 0.99; P = 0.042). Epoetin beta was associated with a slightly higher frequency of thromboembolic events vs control (5.9% vs 4.2% of patients) but thromboembolic-related mortality was identical in both groups (1.1%). Epoetin beta provided a slight beneficial effect on tumour progression and did not impact on early survival or thromboembolic-related mortality.

Indexed as

AdultAgedAged, 80 and overAnemiaDisease ProgressionErythropoietinFemaleHumansMaleMiddle AgedNeoplasmsRandomized Controlled Trials as TopicRecombinant ProteinsSurvival Rateepoetin betaErythropoietinRecombinant Proteins

Identifiers

PMID17117175
PMCPMC2360728
OpenAlexW1991356850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.